ABT-869

SKU
A-2177
  • CAS:796967-16-3
  • Formula:C21H18FN5O
  • MW:375.41
  • Appearance:Crystalline Solid
  • Purity:99%
Product Name Qty
ABT-869
5 mg
$999.48
ABT-869
1 mg
$329.44

ABT-869 is multi-targeted inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR, ICvalue of 4 nM), but has much less activity (ICvalues >1 M) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases. The kinase inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (ICvalues of 2, 4 and 7 nM for PDGFR, KDR and CSF-1R, respectively) and VEGF-stimulated proliferation (0.2 nM ICfor human endothelial cells).

More Information
Alternate Name/Synonyms
Linifanib
SKU
A-2177
CAS #
796967-16-3
Chemical Name
N-[4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL]-N'-(2-FLUORO-5-METHYLPHENYL)UREA
Chemical Formula
C21H18FN5O
Molecular Weight
375.41
Appearance
Crystalline Solid
Purity
99%
Solubility
DMSO
Stability
N/A
Melting Point
180-183 °C
Storage Temp
-20°C
THERAPEUTIC AREA
Oncological Disorders
USE
Linifanib (ABT-869) is a structurally novel, potent inhibitor of receptor tyrosine kinases (RTK), vascular endothelial growth factor (VEGF) use in cancer
MDL NUMBER
MFCD11840918
CHEMACX
X1671178-1
INCHI
InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
SMILES
CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
Peptide sequence
Not Applicable
RTECS
Not Applicable
UN #'S
Not Applicable
PACKING GROUP
Not Applicable
HAZARD CLASS
Not Applicable
Handling
Protect from air and moisture
Promo text for AGS discount
N/A
GHS PICTOGRAMS
Handling Protect from air and moisture
UN #'S Not Applicable
Packing Group Not Applicable
To Top